Abstract | OBJECTIVES: While evidence has mounted regarding the short-term effectiveness of pharmacotherapy for opioid use disorder (OUD), little is known about longer-term psychosocial, economic, and health outcomes. We report herein 12-month outcomes for an observational study enrolling participants who had previously taken part in a long-acting buprenorphine subcutaneous injection (BUP-XR) trial for moderate to severe OUD. METHODS: The RECOVER (Remission from Chronic Opioid Use: Studying Environmental and SocioEconomic Factors on Recovery; NCT03604861) study enrolled participants from 35 US community-based sites. Self-reported sustained opioid abstinence over 12 months and self-reported past-week abstinence at 3-, 6-, 9-, and 12-month visits were assessed. Multiple regression models assessed the association of BUP-XR duration with abstinence, controlling for potential confounders. Withdrawal, pain, health-related quality of life, depression, and employment at RECOVER baseline and 12-month visits were also compared to values collected before treatment in the BUP-XR trial. RESULTS: Of 533 RECOVER participants, 425 completed the 12-month visit (average age 42 years; 66% male); 50.8% self-reported sustained 12-month and 68.0% past-week opioid abstinence. In multiple regressions, participants receiving 12-month versus ≤2-month BUP-XR treatment duration had significantly higher likelihood of sustained opioid abstinence (75.3% vs 24.1%; P = 0.001), with similar results for past-week self-reported abstinence over time. During RECOVER, participants had fewer withdrawal symptoms, lower pain, positive health-related quality of life, minimal depression, and higher employment versus pre-trial visit. CONCLUSIONS: RECOVER participants reported positive outcomes over the 12-month observational period, including high opioid abstinence and stable or improved humanistic outcomes. These findings provide insights into the long-term impact of pharmacotherapy in OUD recovery.
|
Authors | Walter Ling, Vijay R Nadipelli, Arnie P Aldridge, Naoko A Ronquest, Caitlyn T Solem, Howard Chilcoat, Victoria Albright, Courtney Johnson, Susan M Learned, Vishaal Mehra, Christian Heidbreder |
Journal | Journal of addiction medicine
(J Addict Med)
2020 Sep/Oct
Vol. 14
Issue 5
Pg. e233-e240
ISSN: 1935-3227 [Electronic] Netherlands |
PMID | 32187112
(Publication Type: Journal Article, Observational Study)
|
Chemical References |
- Analgesics, Opioid
- Narcotic Antagonists
- Buprenorphine
|
Topics |
- Adult
- Analgesics, Opioid
(therapeutic use)
- Buprenorphine
(therapeutic use)
- Employment
- Female
- Humans
- Male
- Narcotic Antagonists
(therapeutic use)
- Opioid-Related Disorders
(drug therapy)
- Quality of Life
|